Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamyd Medical ABFRA:DMN -3.97%41 Cash Ratio is 15.23 as of May. 2026, which is 128% above its 10-year median of 6.68. GuruFocus rates FRA:DMN with a GF Score™ of 41/100 and a GF Value™ of €0.07 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,379 Biotechnology companies, Diamyd Medical AB ranks better than 88.54% on this metric.
Diamyd Medical AB has a Cash Ratio of 15.23. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Diamyd Medical AB's Cash Ratio or its related term are showing as below:
FRA:DMN'
s Cash Ratio Range Over the Past 10 Years
Min: 1.34 Med: 6.68 Max: 16.27
Current: 15.23
During the past 13 years, Diamyd Medical AB's highest Cash Ratio was 16.27. The lowest was 1.34. And the median was 6.68.
FRA:DMN's Cash Ratio is ranked better than 88.54% of 1379
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:DMN: 15.23
Diamyd Medical AB (FRA:DMN) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Diamyd Medical AB Cash Ratio Related Terms
Diamyd Medical AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DMN vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Diamyd Medical AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (FRA:DMN) has a Cash Ratio of 15.23 as of May. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Diamyd Medical AB and its competitors. This is 128% above median its historical median of 6.68. Over the past decade, Diamyd Medical AB's Cash Ratio has ranged from 1.34 to 16.27. According to the industry distribution chart, Diamyd Medical AB ranks #158 out of 1379 companies in the Biotechnology industry, placing it in the top 11.5%.
Is Diamyd Medical AB's Cash Ratio too high?
Diamyd Medical AB's current Cash Ratio of 15.23 is 128% above median its 10-year median of 6.68. Over the past 10 years, this metric has ranged from a low of 1.34 to a high of 16.27. The Biotechnology industry median Cash Ratio is 2.93. Diamyd Medical AB's value of 15.23 is 419.8% above this industry median. Based on the distribution chart, Diamyd Medical AB ranks #158 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #158 out of 1379 companies for Cash Ratio. This places Diamyd Medical AB in the top 12% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Diamyd Medical AB's value of 15.23 is 419.8% above this benchmark. Historically, Diamyd Medical AB's own Cash Ratio has ranged from 1.34 to 16.27 over the past decade. While the company's 10-year median is 6.68 vs. the industry median of 2.93, Diamyd Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diamyd Medical AB's current Cash Ratio of 15.23 is 419.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Diamyd Medical AB and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current Cash Ratio is 15.23, which is 128% above median its own 10-year median of 6.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 3.6% above its estimated fair value. The current Cash Ratio is 15.23, which is 128% above median its 10-year median of 6.68 and 419.8% above the Biotechnology industry median of 2.93. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current Cash Ratio is 15.23 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued.
The current stock price of €0.07 is trading 3.6% above its estimated GF Value™ of €0.07.
GuruFocus considers Diamyd Medical AB to be Fairly Valued.
Key valuation signals for FRA:DMN:
Cash Ratio: 15.23 (128% above median its 10-year median of 6.68)
GF Value™: €0.07 vs. price of €0.07 (3.6% above fair value)
Industry Position: 419.8% above the Biotechnology median (#158 of 1379)
No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for FRA:DMN
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMN has been successfully added to your 
